SRPT
Sarepta Therapeutics, Inc.
$17.73
-2.48%
2026-10-23
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Key Fundamentals
P/E Ratio
54.14
Forward P/E
7.09
EPS (TTM)
$-1.57
ROE
-9.5%
Revenue Growth (YoY)
-34.3%
Profit Margin
-6.9%
Debt/Equity
69.54
Price/Book
1.29
Beta
0.26
Market Cap
$1.97B
Avg Volume (10D)
2.8M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$23.62
60D Low
$14.75
Avg Volume
3.0M
Latest Close
$17.73
Get breakout alerts for SRPT
Sign up for Breakout Scanner to receive daily notifications when SRPT triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Sarepta Therapeutics, Inc. (SRPT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors SRPT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SRPT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.